1 withdrawn. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
Follow Endometrium Tumor: new trials by email Literature Review of Endometrium Tumor trials Research Report on Endometrium Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Vic-trastuzumab duocarmazine (SYD985) + paclitaxel - HER2-positive Breast Cancer, HER2 Low | Phase 1 | Withdrawn | QuantumLeap Healthcare Collaborative | 2021-07-28 | 2023-11-18 |
Breast Neoplasms (1) · Endometrial Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1)
Adnexal Diseases (1) · Breast Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Ovarian Diseases (1)
Paclitaxel (1) · trastuzumab duocarmazine (1)
QuantumLeap Healthcare Collaborative (1)
United States (1)